Protalix Biotherapeutics Inc
General ticker "PLX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $126.6M
Protalix Biotherapeutics Inc does not follow the US Stock Market performance with the rate: -3.7%.
Estimated limits based on current volatility of 3.4%: low 1.67$, high 1.78$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.07$, 2.48$]
- 2024-12-30 to 2025-12-30 estimated range: [1.06$, 2.50$]
Financial Metrics affecting the PLX estimates:
- Negative: Non-GAAP EPS, $ of 0.05 <= 0.10
- Negative: Operating cash flow per share per price, % of -1.19 <= 2.35
- Positive: Interest expense per share, $ of 0.05 <= 0.14
- Positive: -0.96 < Investing cash flow per share, $ of -0.25
- Positive: Return on assets ratio (scaled to [-100,100]) of 8.96 > 7.10
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term PLX quotes
Long-term PLX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $38.35MM | $47.64MM | $65.49MM |
| Operating Expenses | $58.81MM | $60.65MM | $55.03MM |
| Operating Income | $-20.46MM | $-13.01MM | $10.46MM |
| Non-Operating Income | $-7.12MM | $-1.38MM | $-1.89MM |
| Interest Expense | $7.52MM | $2.53MM | $3.18MM |
| R&D Expense | $29.73MM | $29.35MM | $17.09MM |
| Income(Loss) | $-27.58MM | $-14.40MM | $8.57MM |
| Taxes | $0.00MM | $0.53MM | $0.25MM |
| Profit(Loss) | $-27.58MM | $-14.93MM | $8.31MM |
| Stockholders Equity | $-6.04MM | $-10.64MM | $33.57MM |
| Inventory | $17.95MM | $16.80MM | $19.05MM |
| Assets | $73.67MM | $55.79MM | $84.43MM |
| Operating Cash Flow | $-10.29MM | $-25.00MM | $-1.32MM |
| Capital expenditure | $1.46MM | $0.63MM | $1.15MM |
| Investing Cash Flow | $18.92MM | $-5.04MM | $-16.71MM |
| Financing Cash Flow | $12.08MM | $8.24MM | $24.67MM |
| Earnings Per Share* | $-0.77 | $-0.31 | $0.12 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.